Table 1. Basic clinical data between AMF and NMF groups according to IMR value.
| NMF (n = 50) | AMF (n = 52) | p value | |
| Age (years) | 61.90 ± 9.96 | 62.87 ± 9.64 | 0.620 |
| Gender (female/male) | 19/31 | 21/31 | 0.805 |
| BMI (kg/m2) | 22.55 ± 2.80 | 25.23 ± 3.04 | 0.113 |
| History | |||
| Hypertension | 28 (56.00%) | 30 (57.69%) | 0.863 |
| Diabetes mellitus | 17 (34.00%) | 20 (38.46%) | 0.639 |
| Hyperlipidemia | 13 (26.00%) | 16 (30.77%) | 0.593 |
| Brain infarction | 8 (16.00%) | 12 (23.08%) | 0.457 |
| Current smoker | 24 (48.00%) | 27 (51.92%) | 0.692 |
| LVEF (%) | 59.88 ± 4.30 | 61.13 ± 4.18 | 0.138 |
| TCH (mmol/L) | 3.93 ± 0.96 | 4.21 ± 0.93 | 0.132 |
| TRIG (mmol/L) | 2.06 ± 0.89 | 1.99 ± 0.94 | 0.697 |
| LDL-C (mmol/L) | 2.38 ± 0.88 | 2.58 ± 0.74 | 0.208 |
| HDL-C (mmol/L) | 1.17 ± 0.43 | 1.15 ± 0.33 | 0.739 |
| Scr (μmol/L) | 75.84 ± 14.06 | 74.19 ± 11.90 | 0.524 |
| gHb (%) | 6.28 ± 1.10 | 6.56 ± 0.85 | 0.148 |
| Hb (g/L) | 127.96 ± 13.30 | 129.85 ± 13.90 | 0.486 |
| Hospitalized drug medication | |||
| Aspirin | 30 (60.00%) | 33 (63.46%) | 0.719 |
| Clopidogrel | 8 (16.00%) | 7 (13.46%) | 0.717 |
| Ticagrelor | 3 (6.00%) | 4 (7.69%) | 0.675 |
| Statin | 33 (66.00%) | 32 (61.54%) | 0.639 |
| ACEI/ARB | 24 (48.00%) | 27 (51.92%) | 0.692 |
| β-blocker | 29 (58.00%) | 33 (63.46%) | 0.572 |
Data were expressed as n (%), mean ± SD.
ACEI, angiotension converting enzyme inhibitors; AMF, abnormal microcirculatory function; ARB, angiotensin II receptor blockers; BMI, body mass index; gHb, glycosylated hemoglobin; Hb, hemoglobin; HDL-C, high density lipoprotein cholesterol; IMR, index of microcirculatory resistance; LDL-C, low density lipoprotein; LVEF, left ventricular ejection fraction; NMF, normal microcirculatory function; Scr, serum creatinine; SD, standard deviation; TCH, total cholesterol; TRIG, triglyceride.